• Ryan Center for Sports Medicine
  • Shapiro Ambulatory Center
  • Maximizing Athletic Performance

    Advanced Arthroscopic Surgery

  • Rebuilding Reliable Joints

    Shoulder Replacement & Complex Reconstruction

  • Maximizing Shoulder Range of Motion

    Advanced Cartilage Restoration

  • Helping You Achieve Your Goals

    Patient Centered Care & Excellent Outcomes

  • Play
  • Pause
Home / Research » pHEMA-nHA Encapsulation and Delivery of Vancomycin and rhBMP-2 Enhances its Role as a Bone Graft Substitute

pHEMA-nHA Encapsulation and Delivery of Vancomycin and rhBMP-2 Enhances its Role as a Bone Graft Substitute

Li X, Xu J, Filion TM, Ayers DC, Song J.  pHEMA-nHA encapsulation and deliver of vancomycin and rhBMP-2 enhances its role as a bone graft substitute. Clinical Orthopaedic Related Research. 2013 August:471(8): 2540-7.

Abstract
BACKGROUND: Bone grafts are widely used in orthopaedic procedures. Autografts are limited by donor site morbidity while allografts are known for considerable infection and failure rates. A synthetic composite bone graft substitute poly(2-hydroxyethyl methacrylate)-nanocrystalline hydroxyapatite (pHEMA-nHA) was previously developed to stably press-fit in and functionally repair critical-sized rat femoral segmental defects when it was preabsorbed with a single low dose of 300 ng recombinant human bone morphogenetic protein-2/7 (rhBMP-2/7). QUESTIONS/PURPOSES: To facilitate clinical translation of pHEMA-nHA as a synthetic structural bone graft substitute, we examined its ability to encapsulate and release rhBMP-2 and the antibiotic vancomycin. METHODS: We analyzed the compressive behavior and microstructure of pHEMA-nHA as a function of vancomycin incorporation doses using a dynamic mechanical analyzer and a scanning electron microscope. In vitro release of vancomycin was monitored by ultraviolet-visible spectroscopy. Release of rhBMP-2 from pHEMA-nHA-vancomycin was determined by ELISA. Bioactivity of the released vancomycin and rhBMP-2 was examined by bacterial inhibition and osteogenic transdifferentiation capabilities in cell culture, respectively. RESULTS: Up to 4.8 wt% of vancomycin was incorporated into pHEMA-nHA without compromising its structural integrity and compressive modulus. Encapsulated vancomycin was released in a dose-dependent and sustained manner in phosphate-buffered saline over 2 weeks, and the released vancomycin inhibited Escherichia coli culture. The pHEMA-nHA-vancomycin composite released preabsorbed rhBMP-2 in a sustained manner over 8 days and locally induced osteogenic transdifferentiation of C2C12 cells in culture. CONCLUSIONS: pHEMA-nHA can encapsulate and deliver vancomycin and rhBMP-2 in a sustained and localized manner with reduced loading doses. CLINICAL RELEVANCE: The elasticity, osteoconductivity, and rhBMP-2/vancomycin delivery characteristics of pHEMA-nHA may benefit orthopaedic reconstructions or fusions with enhanced safety and efficiency and reduced infection risk.
 
  • american-academy-orthopaedic-surgeons
  • american-orthopaedic-society-for-sports-med
  • Reserchgate
  • orthopaedic-research-society
  • american-arthroscopic-association-north-america
  • american-shoulder-and-elbow-surgeons
  • boston-medical-center
  • boston-university
  • boston-university-school-of-medicine
  • depuy-synthes
  • boston-university-orthopaedic-surgery
  • easter-orthopaedic-association
  • tornier